University Hospitals Coventry and Warwickshire NHS Trust said the trial findings, published in a medical journal in 2024, external, offered hope to “tens of thousands” and has generated more capacity for treatment.
Consultant Clinical Oncologist Dr Andrew Chan explained it provided evidence needed to support the use of higher doses over a shortened time.
“We have people who have benefited from this treatment and the first patient, who was treated in 2016, is doing very well,” he said.
“SBRT is now our standard treatment for men with low risk and low-intermediate risk prostate cancer not requiring concurrent hormone therapy.”
